This clinical trial is focused on studying a condition called Generalized Myasthenia Gravis (gMG), which is a chronic autoimmune disease that causes muscle weakness. The study is testing a treatment called efgartigimod alfa, which is given through an intravenous infusion, meaning it is administered directly into the bloodstream through a vein. The purpose of the study is to evaluate how different dosing schedules of efgartigimod alfa can maximize and maintain clinical benefits for patients with gMG.

Participants in the study will receive efgartigimod alfa in one of two dosing regimens. The study will compare a continuous regimen, where the medication is given every two weeks, to a cyclic regimen, where the medication is given in cycles. The study will monitor changes in the participants’ symptoms over time to determine which dosing schedule is more effective. The study will also track any side effects or adverse events that participants may experience during the trial.

The trial aims to provide valuable information on how to best use efgartigimod alfa to help manage symptoms of Generalized Myasthenia Gravis. By comparing different dosing regimens, researchers hope to find the most effective way to use this treatment to improve the quality of life for individuals living with this condition.